Revolution Medicines, Inc. (RVMD)

38.73 -0.37 (-0.95%) At close: 4:00PM EST

Revolution Medicines, Inc.

700 Saginaw Drive
Redwood City, CA 94063
United States
650 481 6801
http://www.revmed.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 117

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Mark A. Goldsmith M.D., Ph.D.	CEO, Pres & Chairman	506.3k	N/A	1962
Ms. Margaret A. Horn	COO & Gen. Counsel	386.38k	N/A	1963
Dr. Stephen M. Kelsey M.D., FRCP, FRC Path.	Pres of R&D	426.35k	N/A	1961
Dr. Martin D. Burke	Co-Founder & Chairman of Scientific Advisory Board	N/A	N/A	N/A
Dr. Michael A. Fischbach	Academic Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1981
Dr. Kevan M. Shokat	Academic Co-Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Mr. Jack Anders	VP of Fin. & Principal Accounting Officer	N/A	N/A	1977
Mr. David L. Pompliano	Founding Chief Scientific Officer	N/A	N/A	N/A
Mr. Walter Reiher Ph.D.	Chief Information Officer	N/A	N/A	N/A
Ms. Luan M. Wilfong	Sr. VP of HR	N/A	N/A	N/A

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit targets primarily within the RAS and mTOR signaling pathways. The company's principal product candidate is RMC-4630, an inhibitor of SHP2, which is in Phase 1b/2 study for the treatment of RAS-dependent tumors. Its products in preclinical stage include mutant RAS proteins; SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a mTORC1 inhibitor. Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors. The company was founded in 2014 and is headquartered in Redwood City, California.

Corporate Governance

Revolution Medicines, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.